Research programme: factor Xa inhibitors - Daiichi SankyoAlternative Names: DT-831j; R-142086
Latest Information Update: 13 Oct 2010
At a glance
- Originator Daiichi Sankyo Company
- Class Amidines; Indoles; Pyridines; Small molecules; Sulfonamides
- Mechanism of Action Factor Xa inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Thrombosis